Summary
Only a thyroid C-cell tumor risk/contraindication claim was provided for label comparison; other dosing/timing/pharmacokinetic/general and non-label patent statements were not evaluated against the supplied FDA label excerpts and therefore cannot be confirmed.
Category Scores
Accurate Statements
The claim that OZEMPIC (semaglutide) has an associated risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
Supported by provided label sections 5.1 (thyroid C-cell tumor risk in rodents; human relevance unknown; contraindication counsel) and 4 (contraindications list).
Human relevance of the rodent thyroid C-cell tumor finding has not been determined.
Supported by label section 5.1.
Patient counseling regarding thyroid tumor symptoms is consistent with label (e.g., lump in the neck/hoarseness/dysphagia/dyspnea).
Supported by label section 17 and 5.1.
Unsupported Statements
Ozempic is administered once weekly; patients should administer Ozempic once weekly on the same day each week.
No dosing/administration instructions were provided in the supplied label excerpts.
Ozempic can be taken with or without food.
Not supported by the supplied label excerpts.
The first dose of Ozempic is 0.25 mg; dose titration upward to 0.5 mg, 1 mg, or 2 mg depends on glycemic response and tolerance; weekly timing remains consistent across maintenance doses.
Not supported by the supplied label excerpts.
Semaglutide, the active ingredient in Ozempic, has a half-life of approximately seven days.
Not supported by the supplied label excerpts.
Missed-dose instructions (e.g., less than five days: take missing injection and continue; five days or more: skip and resume next scheduled day).
Not supported by the supplied label excerpts.
Trulicity, Mounjaro, and Bydureon are dosed on a weekly protocol.
Not supported by the supplied OZEMPIC prescribing information excerpts.
The composition-of-matter patent covering semaglutide expires in 2031 in the U.S. and that after 2031 potential biosimilar or generic entry may be allowed.
Patent-expiration and market-entry timing are not addressed in the supplied label excerpts.
Contradictions
Important Omissions
No statement in the evaluated content included the label detail that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC (and may increase unnecessary procedures).
Importance:
Moderate
No inclusion of label detail that significantly elevated serum calcitonin may indicate MTC and that elevated values should prompt further evaluation; and that thyroid nodules noted on exam/imaging should be further evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The specific thyroid C-cell tumor risk and contraindication claim matched label. However, multiple other dosing/administration and missed-dose statements were provided without supporting label excerpts, so their accuracy relative to the supplied prescribing information cannot be confirmed; inaccurate dosing instructions could be clinically risky.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several non-thyroid statements (dose, titration, missed-dose handling, timing, half-life, other products weekly dosing, and patent/market-entry claims) are not supported by the supplied FDA label excerpts and therefore cannot be validated.
Suggested Improvement
Limit claims to the supplied label-supported content (thyroid C-cell tumor risk, contraindication for MTC/MEN 2, and counseling/symptoms). Remove or re-verify dosing/half-life/missed-dose/patent statements using the corresponding sections of the Ozempic prescribing information.